Diagnostics, Genetics, Imaging

Latest Information on Molecular Imaging for Prostate Cancer

The Prostate Cancer Research Institute (PCRI) publishes a periodical entitled Insights which is available by e mail or regular mail.  I strongly advise readers to subscribe electronically.  The February issue discussed several very important topics including molecular imaging.  After initial surgery or radiation prostate cancer treatment, 40% of patients will experience a PSA relapse.  Knowing more »

MRI-Ultrasound-Guided Biopsies Diagnose More High-Risk Prostate Cancers.

Prostate biopsies that combine MRI technology with ultrasound appear to give men better information regarding the seriousness of their cancer, a new study suggests.  The new technology, which uses MRI scans to help doctors biopsy very specific portions of the prostate, diagnosed 30 percent more high-risk cancers than standard prostate biopsies in men suspected of more »

Prostate MRI/Ultrasound Fusion Guided Biopsies for Prostate Cancer Detection

I recently came across a video presentation from the University of Alabama-Birmingham describing in detail the technique of using prostate magnetic resonance imaging (MRI) coupled with ultrasound techniques to guide urologists to specific prostate biopsy targets.  While the video is geared to scientific and medical personnel, it can provide general knowledge of the potential utility more »

1) A “Calculator” to Predict Biopsy Outcomes; 2) Understanding the TNM Staging System Upon Prostate Cancer Diagnosis.

1) Researchers at the University of Texas Health Sciences Center in San Antonio have developed a “calculator” to predict probabilities of biopsy results based upon data such as PSA, age, race, results of digital examination and family history.  To access the “calculator” online, go to http://deb.uthscsa.edu/URORiskCalc/Pages/calcs/jsp.  The “calculator” is based on data from the prostate more »

Possible Link Between Low Vitamin D Levels and Prostate Cancer Risk

A recent study published in Clinical Cancer Research, (May 1, 2014; 20; 2289-99) indicated that men at risk of prostate cancer are more likely to develop an aggressive form of the disease if they are deficient in vitamin D. University of Illinois – Chicago and Northwestern University researchers examined data from 667 men aged 40 more »

1) MRI or Ultrasound-Guided Biopsies; 2) Effect of Diet on Prostate Cancer; and, 3) Two Genes Linked to Aggressive Prostate Cancer.

1) A recent article was published from the Washington University School of Medicine which compared the results of prostate cancer biopsies as guided by magnetic resonance imaging (MRI) with those obtained via ultrasound guidance. It was concluded that MRI-guided biopsies were more likely to find aggressive tumors than those that rely on ultrasound. For specific more »

New 17-Gene Test Enhances Ability to Predict Prostate Cancer Aggressiveness.

Genomic Health Inc., a cancer diagnostics company, recently announced they are now marketing a genomic test for men diagnosed with prostate cancer that will provide better information on how likely it is that their prostate cancer is an aggressive form of the disease needing immediate treatment, or a slow-growing, low-risk form of prostate cancer that more »

All You Need to Know About the Gleason Score and Its Diagnostic Use.

The Johns Hopkins Health Alerts are extremely informative about various health issues including prostate cancer. The latest alert (June 14th)  discussed the Gleason Score, the most important factor in predicting the current state of a prostate cancer. The Gleason Score is based on tumor grade, which is an indication of the tumor’s aggressiveness. The tumor more »

Exercise and Prostate Cancer; Enzalutamide Extends Survival; and, Synergy in Cancer Risk Assessment.

Several articles of interest were recently published in the February-March, 2014 NewsPulse from the Prostate Cancer Foundation (PCF). This information had been presented at the American Association for Cancer Research (AACR) meeting. The first article described the benefits of exercise in men prior to their prostate cancer diagnosis as well as during therapy for their more »

More News on Genetic Screening for Prostate Cancer Involving BRCA1 and BRCA2 Genes Among Others.

It is widely accepted that selected genetic screening is the future of prostate cancer detection. Two interesting articles were recently published describing such screening involving the aggressive breast cancer genes, BRCA1 and BRCA2 among others (CHEK2, PALB2 and ATM). For details, see the following link. In addition, researchers in the United Kingdom have determined that more »

Screening and Treatment News Items from the Prostate Cancer Research Institute (PCRI) Highlights

The Prostate Cancer Research Institute publishes a monthly periodical called “Insights”. At the end of 2013, they also updated their user-friendly and searchable website, http://www.pcri.org. The February 2014 issue of Insights contained considerable information which I will briefly summarize. I encourage you to see the articles in their entirety. First, Dr. John Davis from MD more »

1) Financial Assistance for Prostate Cancer (PC) Patients; 2) Three New Commercially-Available Genetic PC Tests; 3) Phase 2 Clinical Trials for Metastatic PC Patients.

1) Payment Assistance for Under Insured Patients. The Patient Access Network (PAN) Foundation offers financial assistance to prostate cancer patients who lack full insurance coverage, allowing access to treatments previously out of reach. In 2012, PAN started an initiative to raise funds to provide castrate-resistant patients access to new and necessary treatments. To date, 2,200 more »

Highlights of 2013-continued. Inflammation,Diet and Prostate Cancer; FDA Approvalof Xofigo; and, a Guide to Genes and Prostate Cancer.

Chronic inflammation is suspected to play a role in numerous diseases such as heart disease, Alzheimer’s, arthritis and cancer. If this is the case, then could reducing chronic inflammation by dietary means reduce the incidence of prostate cancer for example? This question is being studied extensively and is the focus of an article in the December 20th issue of more »

Highlights of 2013; New Urine Test for Prostate Cancer.

A new urine test for prostate cancer that measures minute fragments of ribonucleic acid (RNA) is now commercially available nationwide through the University of Michigan MLabs. The new test [Mi-Prostate Score (MiPS)], improves the utility of the PSA blood test, increases physicians’ ability to differentiate high-risk prostate tumors from low-risk tumors in patients, and may help more »

A New Urine Test for Prostate Cancer Combining Genetic Biomarkers.

Considerable academic and commercial research efforts are underway in order to identify and utilize genetic biomarkers to aid in the diagnosis and characterization of prostate cancers, to determine their aggressiveness, to ascertain the need for biopsies, and to monitor therapeutic regimens. These have been reviewed in this website’s blog posts dated March 26th, 2012 and more more »

Measuring PSA Activity May Be a Better Predictor of Prostate Cancer Aggressiveness.

Research results recently published online in the August 9th issue of The Prostate (Prostate 2013, DOI:10.1002/pros.22714) suggest that measuring the biological enzymatic activity (or lack thereof) of prostate-specific antigen (PSA) could be used as a predictor of prostate cancer (PCa) aggressiveness.  As we know, the level of PSA in serum is often used to determine the necessity more »